News From the Journals

Adding SBRT to Chemotherapy Reduces Locoregional Recurrence in High-Risk Pancreatic Cancer

November 17, 2026 By Meg Barbor 3 min read
Share Share via Email Share on Facebook Share on LinkedIn Share on X

In the phase II MASTERPLAN trial, the addition of stereotactic body radiotherapy (SBRT) to perioperative chemotherapy significantly reduced locoregional recurrence compared with chemotherapy alone in patients with high-risk, localized pancreatic cancer. SBRT was also associated with longer progression-free survival and overall survival, although the trial was not powered to establish an overall survival benefit. The findings were reported in The Lancet Oncology by Oar et al.

At 12 months, locoregional recurrence was 20.2% with chemotherapy plus SBRT vs 52.0% with chemotherapy alone (subdistribution hazard ratio [sHR] = 0.44; P = .022), without a statistically significant increase in grade 3 or higher adverse events.

Study Details

The multicenter, open-label trial was conducted at 14 hospitals in Australia and New Zealand. It included patients with previously untreated, localized pancreatic ductal adenocarcinoma and at least one high-risk feature, including tumor size greater than 4 cm, extrapancreatic extension, regional lymph node involvement, borderline resectable disease, or locally advanced disease.

A total of 74 patients were included in the intention-to-treat population, with 49 assigned to chemotherapy plus SBRT and 25 to chemotherapy alone. Most patients received modified FOLFIRINOX (fluorouracil, leucovorin, irinotecan, and oxaliplatin), although gemcitabine plus nab-paclitaxel was also permitted.

All patients were scheduled to receive 12 weeks of induction chemotherapy. Those assigned to SBRT received 40 Gy in five fractions following chemotherapy. Patients were then assessed for surgical resection, with additional chemotherapy planned after surgery or for those who remained ineligible for resection.

The primary endpoint was locoregional recurrence at 12 months. Secondary endpoints included progression-free survival, overall survival, surgical outcomes, and safety.

Efficacy Outcomes

After a median follow-up of 3.2 years, median progression-free survival was 11.9 months with chemotherapy plus SBRT vs 6.3 months with chemotherapy alone (HR = 0.44; P = .0018).

Median overall survival was 22 months vs 14.0 months, respectively (HR = 0.45; P = .0061). The P value for this endpoint was considered descriptive.

Among patients with potentially operable disease, surgical resection was performed in 68% of those assigned to SBRT and 59% of those receiving chemotherapy alone (P = .54). Margin-negative (R0) resection was achieved in 62% and 40% of these patients who underwent resection, respectively (P = .44).

Among patients who underwent resection, 80% in the SBRT group received adjuvant chemotherapy compared with 36% in the chemotherapy-alone group (P = .020).

Safety and Study Limitations

Grade 3 or higher adverse events occurred in 70% of patients receiving chemotherapy plus SBRT and 64% receiving chemotherapy alone (P = .27). The most common were diarrhea (15% vs 20%) and thromboembolic events (6% vs 4%).

Serious adverse events of grade 3 or higher occurred in 64% and 56% of patients, respectively (P = .24). Two serious adverse events were attributed to SBRT: grade 2 small bowel obstruction and grade 3 pancreatitis. One treatment-related death from biliary tract infection occurred in the chemotherapy-alone group.

The investigators noted several limitations, including early trial closure because of slow enrollment and insufficient funding; the study enrolled 74 eligible patients instead of the planned 120. They also noted differences in adjuvant chemotherapy use between groups and the inclusion of patients with different levels of disease resectability.

They added that the trial's findings “support the hypothesis that improved locoregional disease control might contribute to better long-term oncological outcomes in selected patients,” although the overall survival finding requires confirmation in a larger trial.

Andrew Oar, MBBS, of Icon Cancer Centre, Gold Coast University Hospital, Queensland, Australia, is the corresponding author.

DISCLOSURE: The trial was funded by the Medical Research Future Fund, Australasian Gastro-Intestinal Trials Group, National Health and Medical Research Council Clinical Trials Centre at the University of Sydney, and Gut Cancer Foundation, New Zealand. For full disclosures of the study authors, visit thelancet.com.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.